sGC stimulators
Compounds of Formulae I′ and I are described, which are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds are also useful for treating, preventing or managing various disorders that are herein disclosed.
1. A method of treating resistant hypertension in a subject in need of treatment, comprising administering a therapeutically effective amount of compound I-324
or a pharmaceutically acceptable salt thereof, to the subject in need of treatment; wherein the subject is on concurrent use of at least three antihypertensive agents belonging to different antihypertensive drug classes selected from the group consisting of angiotensin-converting-enzyme (ACE) inhibitor, angiotensin II receptor blocker (ARB), calcium channel blocker, diuretic, and beta blocker.
2. The method of claim 1 , wherein the angiotensin-converting-enzyme (ACE) inhibitor is captopril, enalapril, ramipril, lisinopril, fosinopril, benazepril, alacepril, or delapril.
3. The method of claim 1 , wherein the angiotensin II receptor blocker (ARB) is azilsartan, irbesartan, candesartan, telmisartan, olmesartan, losartan or valsartan.
4. The method of claim 1 , wherein the calcium channel blocker is amlodipine.
5. The method of claim 1 , wherein the diuretic is hydrochlorothiazide, chlorthalidone, a potassium sparing diuretic, or an aldosterone antagonist.
6. The method of claim 1 , wherein the beta blocker is nebivolol, metoprolol or atenolol.
7. The method of claim 1 , wherein the angiotensin-converting-enzyme (ACE) inhibitor is captopril, enalapril, ramipril, lisinopril, or benazepril; the angiotensin II receptor blocker (ARB) is losartan or valsartan; the calcium channel blocker is amlodipine; the diuretic is hydrochlorothiazide; and the beta blocker is metoprolol or atenolol.
8. The method of claim 5 , wherein the potassium sparing diuretic is amiloride or triamterene.
9. The method of claim 5 , wherein the aldosterone antagonist is eplerenone or spironolactone.